by Maria Zannes | Jul 24, 2018 | News
JULY 20, 2018 As published in GenomeWeb’s 360Dx By Leo O’Connor NEW YORK – BioAffinity Technologies has begun clinical validation of a test for the early detection of lung cancer that uses flow cytometry and detects porphyrin molecules in sputum samples. The San...
by Maria Zannes | Jul 24, 2018 | News
JULY 19, 2018 As published in the San Antonio Business Journal By W. Scott Bailey Roughly four years after its San Antonio launch, cancer diagnostics company bioAffinity Technologies is only months away from taking its initial product — CyPath Lung — to market. The...
by Maria Zannes | May 18, 2018 | News
MAY 15, 2018 As published in Xconomy Texas By David Holley (SAN ANTONIO, TX) bioAffinity, the maker of a cancer diagnostic test, has added Peter Knight, who was the chief of staff for Al Gore when he was in Congress, to its board of directors and is in the process of...
by Maria Zannes | Mar 15, 2018 | News
MARCH 1, 2018 As published in the San Antonio Business Journal By W. Scott Bailey San Antonio-based bioAffinity Technologies has been approved for membership in the Early Detection Research Network, an initiative of the National Cancer Institute. The approval gives...
by Maria Zannes | Dec 29, 2017 | News
DECEMBER 26, 2017 As published in the San Antonio Business Journal By W. Scott Bailey It’s been a landmark year for San Antonio’s biotech industry. Multiple companies have hit major milestones en route to greater international expansion and new product development....
by Maria Zannes | Dec 11, 2017 | News
DECEMBER 8, 2017 As published in the San Antonio Business Journal By W. Scott Bailey In an effort to shore up plans to commercialize its initial product, bioAffinity Technologies is adding more scientific and financial firepower to its arsenal. The San Antonio-based...
